1. Home
  2. NKLR vs FULC Comparison

NKLR vs FULC Comparison

Compare NKLR & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NKLR

Terra Innovatum Global N.V. Ordinary shares

N/A

Current Price

$6.05

Market Cap

500.6M

Sector

Industrials

ML Signal

N/A

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$8.28

Market Cap

535.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKLR
FULC
Founded
2018
2015
Country
Italy
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
500.6M
535.5M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NKLR
FULC
Price
$6.05
$8.28
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
$15.00
$16.38
AVG Volume (30 Days)
507.5K
907.5K
Earning Date
04-01-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.73
$3.17
52 Week High
$12.43
$15.74

Technical Indicators

Market Signals
Indicator
NKLR
FULC
Relative Strength Index (RSI) 69.70 56.51
Support Level $3.94 $6.35
Resistance Level $6.41 $9.99
Average True Range (ATR) 0.44 0.51
MACD 0.17 0.16
Stochastic Oscillator 81.22 100.00

Price Performance

Historical Comparison
NKLR
FULC

About NKLR Terra Innovatum Global N.V. Ordinary shares

Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor SOLO. SOLO is compact yet extremely powerful with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: